{"id":788189,"date":"2023-10-04T16:47:31","date_gmt":"2023-10-04T20:47:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/"},"modified":"2023-10-04T16:47:31","modified_gmt":"2023-10-04T20:47:31","slug":"kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/","title":{"rendered":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13"},"content":{"rendered":"

\nManagement to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope
\n<\/h2>\n
\n

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC International Conference in Boston, Mass. KB-0742 is the company\u2019s internally discovered, highly selective, oral cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-dependent solid tumors.<\/p>\n

A live webcast of the conference call can be accessed under \u201cEvents & Presentations\u201d on the investors section of the Company\u2019s website at ir.kronosbio.com\/events-presentations<\/a>. To participate in the live call, please register using this link<\/a>. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will be informed of the dial-in numbers and PIN. An archived webcast will be available following the event.<\/p>\n

\n Presentation information<\/strong>\n <\/p>\n

\n Poster Title: <\/strong>A First-In-Human Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of Tolerability and Clinical Activity<\/p>\n

\n Presenter: <\/strong>Miguel Villalona-Calero, M.D, City of Hope<\/p>\n

\n Abstract #: <\/strong>B159<\/p>\n

\n Date and Time: <\/strong>Poster Session B | Friday, October 13, 12:30 pm-4:00 pm ET, Level 2, Exhibit Hall D<\/p>\n

\n About Kronos Bio, Inc.<\/strong>\n <\/p>\n

Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC<\/em>-dependent solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK inhibitor, for patients with FLT3-mutated acute myeloid leukemia. The company\u2019s scientific focus is on developing medicines that target the deregulated transcription that is the hallmark of cancer and other serious diseases.<\/p>\n

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.<\/p>\n

\n Company Contact:<\/strong>
\n
Sarah Connors, Vice President of Investor Relations and Corporate Communications
Kronos Bio
857-290-7305
sconnors@kronosbio.com<\/a><\/p>\n

\n Agency Contact:<\/strong>
\n
Brendan Strong, Managing Director
Argot Partners\u00a0\u00a0
212-600-1902
kronosbio@argotpartners.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, … <\/p>\n

Continue reading “Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-788189","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, … Continue reading "Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T20:47:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\\\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13\",\"datePublished\":\"2023-10-04T20:47:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/\"},\"wordCount\":444,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/\",\"name\":\"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\\\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=\",\"datePublished\":\"2023-10-04T20:47:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\\\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/","og_locale":"en_US","og_type":"article","og_title":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk","og_description":"Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, … Continue reading \"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-04T20:47:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13","datePublished":"2023-10-04T20:47:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/"},"wordCount":444,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/","name":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=","datePublished":"2023-10-04T20:47:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0Mzk0NCM1ODU3NDY2IzIyMDMyOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kronos-bio-to-present-interim-data-from-phase-1-dose-escalation-portion-of-ongoing-phase-1-2-kb-0742-study-at-aacr-nci-eortc-and-host-virtual-investor-event-on-october-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1\/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=788189"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788189\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=788189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=788189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=788189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}